The President of Angion Biomedica Corp. (NASDAQ:ANGN), Jay Venkatesan, Just Bought 24% More Shares

Those following along with Angion Biomedica Corp. (NASDAQ:ANGN) will no doubt be intrigued by the recent purchase of shares by Jay Venkatesan, President of the company, who spent a stonking US$730k on stock at an average price of US$2.63. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 24%.

Check out our latest analysis for Angion Biomedica

The Last 12 Months Of Insider Transactions At Angion Biomedica

Notably, that recent purchase by Jay Venkatesan is the biggest insider purchase of Angion Biomedica shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$2.96. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

In the last twelve months insiders purchased 404.00k shares for US$1.0m. But insiders sold 1.40k shares worth US$28k. In total, Angion Biomedica insiders bought more than they sold over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 14% of Angion Biomedica shares, worth about US$12m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Angion Biomedica Insiders?

The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Angion Biomedica we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Angion Biomedica. At Simply Wall St, we've found that Angion Biomedica has 4 warning signs (1 doesn't sit too well with us!) that deserve your attention before going any further with your analysis.

But note: Angion Biomedica may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.